ERYC® capsules are a delayed-release erythromycin (a macrolide antibiotic) produced by Mayne Pharma using proprietary pellet technology.
Indicated for the treatment of a wide variety of bacterial infections, ERYC is formulated to protect erythromycin degrading in the acidic environment of the stomach, for optimal absorption in the intestine.
ERYC® capsules are available in two dose strengths, 250 mg and 333 mg.
ERYC® capsules are currently sold in Australia, Canada, Sweden, Norway and the US.
Opportunities remain for licensing.